Disclaimer:
MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.
References:
1) Leung TW, et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Poster number A0113. Presented 6th May, ARVO 2025.
2) Determined using available published evidence of myopia management spectacle lenses as of May 2025.
3) Fulton J.M.,McCullough S.J.,Saunders K.J.,Richardson P., Logan N.S., Whayeb Y., Williamson P., Barr H., Nagra M., Pardhan S., Shah R., Vlasak N. Multi-Site Observational Study of Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in UK children: 2-year results. IMC Conference Presentation (2024) https://www.hoyavision.com/visionary-knowlegde/blogs-and-article/conference-imc-2024/
4) Jong M, Jonas JB, Wolffsohn JS, et al. IMI 2021 Yearly Digest. Invest. Ophthalmol. Vis. Sci. 2021;62(5):7. https://doi.org/10.1167/iovs.62.5.7
5) Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-8
6) HOYA data on file. Transmission, traffic light recognition, and UV blocking test for MiYOSMART clear and MiYOSMART sun spectacle lenses. 02/2023. Tests were conducted at room temperature (23°C).
7) HOYA data on file. PSF test on MiYOSMART clear and sun spectacle lenses. 06/2022.
*Brien Holden Vision Institute; 2 Shanghai Eye Disease Prevention and Treatment Center https://guidelines.brienholdenvision.org, accessed 16.08.1018.